3Costa L, Major PP. Effect of bisphosphonates on pain and quality of Life in patients with bone metastases. Nat Clin Pract Oncol. 2009 Feb 3.
4Hatoum HT, Lin SJ, Smith MR, Barghout V, Lipton A. Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a National Medical claims database. Cancer 2008 Sep 15, 113(6): 1438-45.
5Kretzschmar A, Wiege T, Al-Batran SE, Hinrichs HF, Kindler M, Steck T, Illiger HJ, Heinemann V, Schmidt K, Haus U, Kirner A, Ehninger G. Rapid and sustained influence of intravenous zoledronic Acid on course of pain and analgesics consumption in patients with cancer with bone metastases: a multicenter open-label study over 1 year. Support Cancer Ther. 2007 Sep 1; 4(4): 203-10.
6Di, Lijunl; Pen, Jun; Yan, Ying. A multicenter phase Ⅱ trial of domestic product ofzoledronic acid in the treatment of malignant hypercalcemia. The Chinese-German Journal of Clinical Oncology, Volume 6, Number 4, August 2007, pp. 393-395(3).
2[1]Clines GA and Guise TA.Hypercalcaemia of malignancy andbasic research on mechanisms responsiblefor osteolytic and osteoblastic metastasisto bone.Endocrine Related Cancer,2005,12:549
3[2]Bukowski JF,Dascher CC,Das H.Alternative bisphosphonate targets and mechanisms of action.Biochem Biophys Res Commun,2005,328 (3):746
4[3]Ferretti G,Fabi A,Carlini P,et al.Zoledronic-acid-induced circulating level modifications of angiogenic factors,metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients.Oncology,2005,69 (1):35
5[4]Clezardin P,Ebetino FH,Fournier PG.Bisphosphonates and cancer-induced bone disease:Beyond their antiresorptive activity.Cancer Res,2005,65 (12):4971
6[5]Pavlakis N,Schmidt R,Stockler M.Bisphosphonates for breast cancer.Cochrane Database Syst Rev,2005,20; (3):CD003474
7[6]Hillner BE,Ingle JN,Chlebowski RT,et al.American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer.J Clin Oncol,2003,21:4042
8[7]Peter R,Mishra D,Fraser WD.Severe hypocalcaemia after being given intravenous bisphophonate.BMJ,2004,328(7435):335
9[8]Fraunfelder FW,Fraunfelder FT.Bisphosphonates and ocular inflammation.N Engl J Med,2003,348 (12):1187
10[9]Ruggiero SL,Mehrotra B,Rosenberg TJ,et al.Osteonecrosis of the jaws associated with the use of bisphosphonates:A review of 63 cases.J Oral Maxillfac Sug,2004,62 (5):527
1Roelofs AJ, Thompson K, Ebetino FH, et al. Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages[J]. Curr Pharm Des, 2010, 16(27): 2950-2960.
2Van den Wyngaert T, Huizing MT, Fossion E, et al. Bisphosphonates in ontology: rising stars or fallen heroes[J].Oncologist, 2009, 14(2): 181-191.
3Watts NB, Brown JP, Cline G. Risedronate on 2 consecutive days a month reduced vertebral fracture risk at lyear compared with historical placebo[J]. J Clin Densitom, 2010, 13(1): 56-62.
4Hadji P.Managing bone health with zoledronic aci-d:a review of randomized clinical study results.Climacteric,2011,14:321~332.
5Allan L.Acid:multiplicity of use across the cancer continuum.Anticancer Ther,2011,11:999~1012.
6Eidtmann H,Boer R,Bundred N.Efficacy of zol-edronic acid in postmenopausal women with ea-rly breast cancer receiving adjuvant letrozole:36-month results of the ZO-FAST study.Ann Oncol,2010,21:2188~2194.
7Evdokiou A,Labrinidis A,Bouralexis S.Inducti-on of cell death of human osteogenic sarcoma cel-ls by zoledronic acid resembles anoikis.Bone,2003,33:216~218.
